Abstract: | The appreciation of biocompatibility between the evolution of physiologic processes of healthy animal organism and the glycoside-furostanolic treatment was accomplished in vivo, on experimental models that are adequate to preliminary researches of pharmaco-toxicology.
The moderate decrease of the total number of circulator erythrocyte – correlated as sense and amplitude, with the level of haemoglobin and hematocrit – and the low degree of leucopoenia revealed the moderated toxic impact of the biosynthesis and semi-biosynthesis extract over the hemo- and leucopoiesis organs. The record of some plasmatic hyper- or hypoproteinemia, associated with plasmatic hypo- or hyperalbuminemia and hypoglobulinemia, of some moderate hypoglycaemia, associated with hyper- or hypolactacidemia, of a minor hipolipemia, correlated with plasmatic hypercholesterolemia and with low level of concentration of free plasmatic fatty acids, suggests an interference of the biosynthesis agent or the one of semi synthesis with the tissue metabolic processes.
This interaction is concretised through the modification, in normal limits and not in pathologic limits, of some plasmatic biochemical parameters. The assemble of results – through the prism of some reference criteria in the establishing of the toxicity degree of some new potential medicamentary agents – argue the moderate degree of toxicity of native glycoside-furostanolic bio-eradicators, pharmaco-dynamic active over the normal cells of animal organism and especially over the organs that are directly implicated in the maintaining of the intern medium homeostasis. |
